SS-31 (Elamipretide)
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Mitochondria-targeting peptide that improves mitochondrial function and reduces oxidative stress.
Reported benefits
Enhanced mitochondrial function, reduced oxidative stress, potential heart failure treatment
Protocols & dosing
Typical dosage: Clinical trials ongoing (research).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
SS-31 (Elamipretide) is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Clinical trials. Side effects under study
References
No external sources have been catalogued for this article yet.
Related peptides
Categories: Anti-aging & Longevity